Satraplatin

Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM) ; shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active.Chemotherapeutic Agents, Phase 2 Clinical (In Vitro) :Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells.